- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Host-guest interaction-based supramolecular prodrug self-assemblies for GSH-consumption augmented chemotherapy. (Pubmed Central) - Jul 10, 2022 In this study, the host-guest interactions between water-soluble pillar[6]arene (WP[6]) and chlorambucil-arylboronic acid (Cb-BA) were utilized to construct supramolecular prodrug self-assemblies (SPSAs) with specific stimuli-responsive property...Benefiting from the functionality of BA-Cur conjugates, the GSH levels could be significantly downregulated, paving a novel way to enhance chemotherapeutic efficacy. In vitro and in vivo investigations demonstrated that this two-pronged GSH-depletion strategy could amplify the cellular oxidative stress and achieve excellent anti-tumor efficacy.
- |||||||||| Leukeran (chlorambucil) / GSK
chlorambucil? (Twitter) - Jul 5, 2022
- |||||||||| Retrospective data, Journal: Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience. (Pubmed Central) - Jun 25, 2022
The most common type of systemic therapy for MF included low-dose methotrexate (61%), interferon-alpha (58%), bexarotene (28%), and chlorambucil (25%)...Only the minority of patients received innovative targeted agents including brentuximab vedotin, mogamulizumab, or pembrolizumab...Overall, the survival parameters of our CTCL cohort are comparable to those previously published by other groups. In conclusion, our analysis of 118 real world cohort of consecutive CTCL patients treated at the single center confirmed the efficacy of immune response modifiers and underlines the urgent need for ample implementation of innovative agents and their combinations into earlier lines of therapy.
- |||||||||| Review, Journal, IO biomarker: SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. (Pubmed Central) - Jun 22, 2022
In the second case, a patient with CLL and del 17p develops a Richter transformation to diffuse large B-cell lymphoma after treatment with obinutuzumab, chlorambucil, ibrutinib, venetoclax, and idelalisib...The literature pertaining to these two scenarios is reviewed, including the role of available targeted therapies, chemoimmunotherapy, and hematopoietic cell transplantation. Emerging novel therapies, including reversible BTK inhibitors and CAR T cell therapy, are discussed.
- |||||||||| Mustargen (mechlorethamine) / Recordati, Leukeran (chlorambucil) / GSK
Journal: Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy. (Pubmed Central) - May 19, 2022 In 1942, the discovery of nitrogen mustard as an alkylating agent was a tremendous breakthrough in cancer chemotherapy...This review focus on the versatile use of alkylating agents and the structure activity relationship (SAR) of each class of these compounds. This could provide an understanding for design and synthesis of new alkylating agents having enhanced target specificity and adequate bioavailability.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS () - May 13, 2022 - Abstract #EHA2022EHA_2297; Other comparators included treat-to-progression therapies, such as ibrutinib (IBR), and a 6-month course of bendamustine + rituximab (BR)...Thus, VenG with a 12-month fixed duration, has lower total costs and is more efficacious ("dominant") over all comparators in the CEM. OWSA analyses show that the results are robust, and in the PSA VenG is dominant over all the comparators considered, ICER is ≤$ 6,011.20 (1 GDP per capita for Argentina, 2020), /QALY in 97% of the iterations CE Results Conclusion This study shows that in Argentina, VenG would be dominant treatment option (better results and lower costs) compared with ClbG, BR and IBR in the treatment of first-line unfit CLL patients.
- |||||||||| Campath (alemtuzumab) / Sanofi, Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER () - May 13, 2022 - Abstract #EHA2022EHA_1549; Alemtuzumab, cladribine, fludarabine, lenalidomide, and vincristine were first-line therapy in 1 (0.9%) patient each...One in 4 patients with LGLL had a concomitant autoimmune condition, and 25% had a concomitant hematologic condition or hematologic malignancy at the time of initial diagnosis. Approximately a third of all patients who needed LGLL treatment did not achieve a response to frontline therapy, suggesting that newer treatments are needed to improve outcomes of this rare disease.
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
REAL-WORLD TREATMENT PATTERNS OF PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES (US) () - May 13, 2022 - Abstract #EHA2022EHA_1243; In 2L, 16% of patients used ibrutinib, 12% a bendamustine + rituximab regimen, and 4% chlorambucil...Among US patients with CLL, rituximab, bendamustine + rituximab, and ibrutinib were identified as the most used 1L regimens, and the latter two as the most used 2L regimens. As novel therapies are increasingly used, and genetic testing becomes more available, further research will be needed to evaluate the changes in the way CLL is treated and its effects on clinical outcomes.
- |||||||||| Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
EFFICACY OF FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A BAYESIANNETWORK META-ANALYSIS. () - May 13, 2022 - Abstract #EHA2022EHA_1224; P3, P4 Results from this indirect treatment comparison suggested that the PFS for zanubrutinib may be statistically significantly better than immunochemotherapy. Findings from this study require validation with further large scale RCTs with longer follow up time.
- |||||||||| Calquence (acalabrutinib) / AstraZeneca
ACALABRUTINIB RELATED INFECTIOUS COMPLICATIONS-A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE III RCT () - May 13, 2022 - Abstract #EHA2022EHA_1213; In the ELEVATE -TN study the comparator arm included the combination of chlorambucil and obinutuzumab...We noted a substantial heterogeneity across trials included in our analysis. Conclusion Our meta-analysis demonstrated that patients on acalabrutinib-containing regimens experienced a significantly lower relative risk of infections compared to non-acalabrutinib-based therapies. There were significantly lower risks of URTI and infection related treatment discontinuations with acalabrutinib therapy in patients with CLL.
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
TREATMENT OF YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN TUNISIA: FCR STILL STANDARD FOR FIRST-LINE THERAPY () - May 13, 2022 - Abstract #EHA2022EHA_1212; Background Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+,CD5+,and CD23+.Fludarabine,cyclophosphamide and rituximab (FCR) is recommended as first-line therapy for fit patients who are younger than 65 years and have no 17p deletion/ TP53 mutation...Five patients received chlorambucil.10 had CLB-Rituximab and 21 had FCR...Death rate was 7.89% (6 patients of which 3 received FCR). Conclusion FCR remains the first-line therapy for fit patients who are younger than 65 years and have no 17p deletion /mutation TP53 in Tunisia .Our patients have a good tolerance to the drugs and few infectious episodes have occurred.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
INCIDENCE, TREATMENT AND OUTCOME OF PATIENTS WITH RICHTER'S SYNDROME: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS () - May 13, 2022 - Abstract #EHA2022EHA_1003; Seven patients received treatment including ibrutinib or venetoclax, and 3 patients received treatment not including one or more of the abovementioned regimens...Of the 29 remaining patients, 17 (19%) were treated with a R-based chemotherapy regimen including R-PECC and R-bendamustine, and 12 (14%) patients did not receive therapy...Conclusion In this contemporary population-based study, concurrent RS patients have superior OS, while survival among treated RS patients is very poor. Our data underline the importance of development of new strategies, specifically aiming at treated RS patients.
- |||||||||| cisplatin / Generic mfg.
Journal: Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives. (Pubmed Central) - May 4, 2022 Cisplatin(IV) derivative formation further improved the amount of platinum accumulated in tumors after intravenous injection compared to free cisplatin therapy (2.7-5.4 folds increment) and reduced drug-erythrocyte interactions. Overall, the results highlighted the potential of cisplatin(IV) agents in resolving cisplatin drug delivery challenges and denoted the critical role of axial ligand selection in Pt(IV) prodrug designing.
- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Coordinately Tethered Iron(III) Fluorescent Nanotheranostic Polymer Ascertaining Cancer Cell Mitochondria Destined Potential Chemotherapy and T-Weighted MRI Competency. (Pubmed Central) - Apr 28, 2022 Toward the accomplishment of this goal, chlorambucil (chemotherapeutic agent), biotin (receptor targeting agent), a triphenylphosphonium segment (mitochondriotropic agent), and an iron rhodamine complex (integrated fluorescence-MR imaging agent) were tethered under a single polymer...Furthermore, cytotoxicity experiments demonstrated the enhanced anticancer efficacy in both cancer cell lines. Therefore, effective and precise chemotherapy through sequential receptor-mitochondria targeting and integrated fluorescence-MR imaging would have attractive potential for decisive dose-determination by constantly monitoring the subject area of interest.
- |||||||||| Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Efficacy of first-line treatment for chronic lymphocytic leukemia: A Bayesian network meta-analysis. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6237; P3, P4 Results from this indirect treatment comparison suggested that the PFS for zanubrutinib may be statistically significantly better than immunochemotherapy. Findings from this study require validation with further large scale RCTs with longer follow up time.
|